The hexosamine biosynthetic pathway (HBP) is a metabolic branch of glycolysis that produces UDP-GlcNAc, the sole donor substrate for O-GlcNAcylation. It integrates inputs from glucose, glutamine, acetyl-CoA, and uridine to generate a critical signaling molecule[1].
Why it matters for neurodegeneration: The HBP produces UDP-GlcNAc, which is converted by OGT into O-GlcNAc-modified proteins including tau, α-synuclein, and synaptic proteins. Reduced HBP flux → less O-GlcNAcylation → increased tau phosphorylation and aggregation[2].
Fructose-6-phosphate (F6P) enters the HBP from glycolysis. This represents the glucose-dependent input to the pathway.
Glutamine:fructose-6-phosphate amidotransferase (GFAT) catalyzes the committed step, converting F6P to Glucosamine-6-Phosphate using glutamine as the nitrogen source[3]:
GFAT is the rate-limiting enzyme of the HBP:
| Property | Value |
|---|---|
| Gene | GFPT1 (ubiquitous), GFPT2 (muscle) |
| EC Number | 2.6.1.16 |
| Feedback inhibition | UDP-GlcNAc inhibits GFAT (product feedback) |
| Transcriptional regulation | SP1, nutritional status |
Glucosamine-6-phosphate is acetylated by GlcNAc-6-phosphate acetyltransferase (GNA3) using acetyl-CoA:
This step integrates the acetyl-CoA (fatty acid/glucose oxidation) input into the pathway.
GlcNAc-1-phosphate uridylyltransferase (AGX1/AGX2) converts GlcNAc-1-phosphate to UDP-GlcNAc using UTP:
Phosphoglucomutase first converts GlcNAc-6-P to GlcNAc-1-P.
UDP-GlcNAc is the universal donor for O-GlcNAcylation. It is consumed by:
In Alzheimer's disease, brain hypometabolism is one of the earliest detectable biomarkers[4]:
This creates a vicious cycle: hypometabolism reduces O-GlcNAcylation, which accelerates tau pathology, which further impairs neuronal metabolism.
OGA inhibitors like FNP-223 and LY-3372689 bypass the HBP limitation by blocking the removal of O-GlcNAc[6]:
Glutamine is the nitrogen donor for GFAT (step 2). In aging and neurodegeneration:
Uridine is required for UDP-GlcNAc synthesis. In aging:
| Enzyme | Gene | EC Number | Role in Neurodegeneration |
|---|---|---|---|
| GFAT | GFPT1, GFPT2 | 2.6.1.16 | Rate-limiting; UDP-GlcNAc feedback inhibition |
| GNA3 | GNPNAT1 | 2.3.1.4 | Acetyltransferase; links acetyl-CoA to HBP |
| AGX | AGX1, AGX2 | 2.7.7.23 | Uridylyltransferase; final step to UDP-GlcNAc |
| PGM3 | PGM3 | 5.4.2.3 | Phosphoglucomutase; GlcNAc-6-P to GlcNAc-1-P |
| Strategy | Approach | Status |
|---|---|---|
| GFAT activation | Increase first committed step | Preclinical |
| Uridine supplementation | Increase UTP precursor | Explored in metabolic disorders |
| Glutamine supplementation | Increase nitrogen donor | Theoretical, limited BBB penetration |
| Acetyl-CoA boosting | Enhance acetylation step | Not specific to HBP |
| OGA inhibition | Bypass HBP limitation | Multiple Phase 2 programs |
Enhancing O-GlcNAcylation by boosting HBP is challenging because:
This explains why OGA inhibitors have advanced further than HBP-boosting approaches.
Wellcome Trust Case Control Consortium. OGT activity linked to hexosamine biosynthetic pathway flux. Nature Genetics. 2015. ↩︎ ↩︎
Schwartz KR, et al. O-GlcNAc modification of tau and APP: therapeutic targets. Journal of Alzheimer's Disease. 2022. ↩︎ ↩︎
McKnight NC, et al. GFAT: rate-limiting enzyme of the hexosamine pathway. Journal of Biological Chemistry. 2010. ↩︎
Cunnane SC, et al. Brain glucose metabolism in health, aging, and neurodegeneration. Neuroscience & Biobehavioral Reviews. 2020. ↩︎
Knecht H, et al. O-GlcNAcylation of tau in Alzheimer's disease brain. Acta Neuropathologica. 2011. ↩︎
Zhang Z, et al. OGT-mediated O-GlcNAcylation protects neurons against metabolic stress. Cell Death & Disease. 2020. ↩︎
Liu Y, et al. Glutamine availability regulates HBP flux and O-GlcNAcylation. Cell Metabolism. 2016. ↩︎